Skip to main content

Advertisement

SpringerLink
Log in

Viewpoint on handling anti-TNF failure in psoriasis

  • Concise Communication
  • Published:
Archives of Dermatological Research Aims and scope Submit manuscript

Abstract

An association among the occurrence of antidrug antibodies (ADAs), diminished trough serum drug levels (TSDLs) and non-response or loss of response has been described for several tumor necrosis factor alpha (TNF) blocking agents in a variety of diseases, including psoriasis. In a series of ten psoriasis patients with primary or secondary failure, or adverse reactions during anti-TNF therapy, we measured ADAs and TSDLs in patient serum using radioimmunoassay and ELISA, respectively. By proposing a treatment algorithm derived from research in this field, we show that measuring ADAs and TSDLs in psoriasis patients provides a more structured approach to clinical decision making for psoriasis patients who fail anti-TNF therapy.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

References

  1. (EMEA) EAftEoMP (2007) Guideline on immunogenicity assessment of biotechnology-derived therapeutic proteins. EMEA/CHMP/BMWP/14327/2006

  2. Afif W, Loftus EV Jr, Faubion WA, Kane SV, Bruining DH, Hanson KA, Sandborn WJ (2010) Clinical utility of measuring infliximab and human anti-chimeric antibody concentrations in patients with inflammatory bowel disease. Am J Gastroenterol 105(5):1133–1139

    Article  PubMed  CAS  Google Scholar 

  3. Bartelds GM, Wijbrandts CA, Nurmohamed MT, Stapel S, Lems WF, Aarden L, Dijkmans BA, Tak PP, Wolbink GJ (2010) Anti-infliximab and anti-adalimumab antibodies in relation to response to adalimumab in infliximab switchers and anti-tumour necrosis factor naive patients: a cohort study. Ann Rheum Dis 69(5):817–821

    Article  PubMed  CAS  Google Scholar 

  4. Chavez-Lopez MA, Delgado-Villafana J, Gallaga A, Huerta-Yanez G (2005) Severe anaphylactic reaction during the second infusion of infliximab in a patient with psoriatic arthritis. Allergol Immunopathol (Madr) 33(5):291–292

    Article  CAS  Google Scholar 

  5. Daien CI, Daien V, Parussini E, Dupuy AM, Combe B, Morel J (2012) Etanercept concentration in patients with rheumatoid arthritis and its potential influence on treatment decisions: a pilot study. J Rheumatol 39(8):1533–1538

    Article  PubMed  CAS  Google Scholar 

  6. Dore RK, Mathews S, Schechtman J, Surbeck W, Mandel D, Patel A, Zhou L, Peloso P (2007) The immunogenicity, safety, and efficacy of etanercept liquid administered once weekly in patients with rheumatoid arthritis. Clin Exp Rheumatol 25(1):40–46

    PubMed  CAS  Google Scholar 

  7. Edrees AF, Misra SN, Abdou NI (2005) Anti-tumor necrosis factor (TNF) therapy in rheumatoid arthritis: correlation of TNF-alpha serum level with clinical response and benefit from changing dose or frequency of infliximab infusions. Clin Exp Rheumatol 23(4):469–474

    PubMed  CAS  Google Scholar 

  8. Guenther LC (2011) Combination therapy of biologics with traditional agents in psoriasis. Skin Therapy Lett 16(6):1–3

    PubMed  Google Scholar 

  9. Herrier RN (2011) Advances in the treatment of moderate-to-severe plaque psoriasis. Am J Health Syst Pharm 68(9):795–806

    Article  PubMed  CAS  Google Scholar 

  10. Hyrich KL, Lunt M, Watson KD, Symmons DP, Silman AJ, British Society for Rheumatology Biologics R (2007) Outcomes after switching from one anti-tumor necrosis factor alpha agent to a second anti-tumor necrosis factor alpha agent in patients with rheumatoid arthritis: results from a large UK national cohort study. Arthritis Rheum 56(1):13–20

    Article  PubMed  CAS  Google Scholar 

  11. Jamnitski A, Bartelds GM, Nurmohamed MT, van Schouwenburg PA, van Schaardenburg D, Stapel SO, Dijkmans BA, Aarden L, Wolbink GJ (2011) The presence or absence of antibodies to infliximab or adalimumab determines the outcome of switching to etanercept. Ann Rheum Dis 70(2):284–288

    Article  PubMed  CAS  Google Scholar 

  12. Jamnitski A, Krieckaert CL, Nurmohamed MT, Hart MH, Dijkmans BA, Aarden L, Voskuyl AE, Wolbink GJ (2012) Patients non-responding to etanercept obtain lower etanercept concentrations compared with responding patients. Ann Rheum Dis 71(1):88–91

    Article  PubMed  CAS  Google Scholar 

  13. Lecluse LL, de Groot M, Bos JD, Spuls PI (2009) Experience with biologics for psoriasis in daily practice: switching is worth a try. Br J Dermatol 161(4):948–951

    Article  PubMed  CAS  Google Scholar 

  14. Lecluse LL, Driessen RJ, Spuls PI, de Jong EM, Stapel SO, van Doorn MB, Bos JD, Wolbink GJ (2010) Extent and clinical consequences of antibody formation against adalimumab in patients with plaque psoriasis. Arch Dermatol 146(2):127–132

    Article  PubMed  CAS  Google Scholar 

  15. Lecluse LL, Piskin G, Mekkes JR, Bos JD, de Rie MA (2008) Review and expert opinion on prevention and treatment of infliximab-related infusion reactions. Br J Dermatol 159(3):527–536

    Article  PubMed  CAS  Google Scholar 

  16. Leman J, Burden AD (2012) Sequential use of biologics in the treatment of moderate-to-severe plaque psoriasis. Br J Dermatol 167(Suppl 3):12–20

    Article  PubMed  CAS  Google Scholar 

  17. Leonardi CL, Kimball AB, Papp KA, Yeilding N, Guzzo C, Wang Y, Li S, Dooley LT, Gordon KB, investigators Ps (2008) Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1). Lancet 371(9625):1665–1674

    Article  PubMed  CAS  Google Scholar 

  18. Leonardi CL, Powers JL, Matheson RT, Goffe BS, Zitnik R, Wang A, Gottlieb AB, Etanercept Psoriasis Study G (2003) Etanercept as monotherapy in patients with psoriasis. N Engl J Med 349(21):2014–2022

    Article  PubMed  CAS  Google Scholar 

  19. Maser EA, Villela R, Silverberg MS, Greenberg GR (2006) Association of trough serum infliximab to clinical outcome after scheduled maintenance treatment for Crohn’s disease. Clin Gastroenterol Hepatol 4(10):1248–1254

    Article  PubMed  CAS  Google Scholar 

  20. Mazzotta A, Esposito M, Costanzo A, Chimenti S (2009) Efficacy and safety of etanercept in psoriasis after switching from other treatments: an observational study. Am J Clin Dermatol 10(5):319–324

    Article  PubMed  Google Scholar 

  21. Mease PJ, Ory P, Sharp JT, Ritchlin CT, Van den Bosch F, Wellborne F, Birbara C, Thomson GT, Perdok RJ, Medich J, Wong RL, Gladman DD (2009) Adalimumab for long-term treatment of psoriatic arthritis: 2-year data from the Adalimumab Effectiveness in Psoriatic Arthritis Trial (ADEPT). Ann Rheum Dis 68(5):702–709

    Article  PubMed  CAS  Google Scholar 

  22. Mrowietz U, Kragballe K, Reich K, Spuls P, Griffiths CE, Nast A, Franke J, Antoniou C, Arenberger P, Balieva F, Bylaite M, Correia O, Dauden E, Gisondi P, Iversen L, Kemeny L, Lahfa M, Nijsten T, Rantanen T, Reich A, Rosenbach T, Segaert S, Smith C, Talme T, Volc-Platzer B, Yawalkar N (2011) Definition of treatment goals for moderate to severe psoriasis: a European consensus. Arch Dermatol Res 303(1):1–10

    Article  PubMed  CAS  Google Scholar 

  23. Reich K, Nestle FO, Papp K, Ortonne JP, Evans R, Guzzo C, Li S, Dooley LT, Griffiths CE (2005) Infliximab induction and maintenance therapy for moderate-to-severe psoriasis: a phase III, multicentre, double-blind trial. Lancet 366(9494):1367–1374

    Article  PubMed  CAS  Google Scholar 

  24. Smith CH, Anstey AV, Barker JN, Burden AD, Chalmers RJ, Chandler DA, Finlay AY, Griffiths CE, Jackson K, McHugh NJ, McKenna KE, Reynolds NJ (2009) Ormerod AD (2009) British Association of Dermatologists’ guidelines for biologic interventions for psoriasis. Br J Dermatol 161(5):987–1019

    Article  PubMed  CAS  Google Scholar 

  25. Spuls PI, Lecluse LL, Poulsen ML, Bos JD, Stern RS, Nijsten T (2010) How good are clinical severity and outcome measures for psoriasis?: quantitative evaluation in a systematic review. J Invest Dermatol 130(4):933–943

    Article  PubMed  CAS  Google Scholar 

  26. Takeuchi T, Miyasaka N, Tatsuki Y, Yano T, Yoshinari T, Abe T, Koike T (2011) Baseline tumour necrosis factor alpha levels predict the necessity for dose escalation of infliximab therapy in patients with rheumatoid arthritis. Ann Rheum Dis 70(7):1208–1215

    Article  PubMed  CAS  Google Scholar 

Download references

Acknowledgments

Dr. S. Bracke is funded by an IWT Grant (091208) (‘Flemish government agency for Innovation by Science and Technology’).

Conflict of interest

None.

Author information

Authors and Affiliations

  1. Department of Dermatology, Ghent University Hospital, De Pintelaan 185, 9000, Ghent, Belgium

    Stefanie Bracke & Jo Lambert

Authors
  1. Stefanie Bracke
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Jo Lambert
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Stefanie Bracke.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Bracke, S., Lambert, J. Viewpoint on handling anti-TNF failure in psoriasis. Arch Dermatol Res 305, 945–950 (2013). https://doi.org/10.1007/s00403-013-1418-6

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00403-013-1418-6

Keywords

Search

Navigation